Overall response rate stratified by novel SA vs CA in patients with R/R TCL in phase I, II, and III clinical trials lacking histological subtype–specific responses
| . | Novel SA . | CC . | P value . |
|---|---|---|---|
| Phase I | 0.43 [0.32, 0.54] (n = 6)* | 0.40 [0.10, 0.80] (n = 1) | .9 |
| Phase II | 0.30 [0.18, 0.44] (n = 7) | 0.75 [0.5, 0.92] (n = 4) | .002 |
| Phase III | 0.40 [0.28, 0.54] (n = 3) | 0.35 [0.18, 0.56] (n = 1) | .64 |
| . | Novel SA . | CC . | P value . |
|---|---|---|---|
| Phase I | 0.43 [0.32, 0.54] (n = 6)* | 0.40 [0.10, 0.80] (n = 1) | .9 |
| Phase II | 0.30 [0.18, 0.44] (n = 7) | 0.75 [0.5, 0.92] (n = 4) | .002 |
| Phase III | 0.40 [0.28, 0.54] (n = 3) | 0.35 [0.18, 0.56] (n = 1) | .64 |
Numbers in parenthesis represent number of clinical trials included for analysis in that category.